Goserelin Acetate Implant
NDC Package 60440-0960-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Goserelin Acetate implants is goserelin is used in men to treat prostate cancer. This formulation utilizes a implant delivery system. Marketed by Astrazeneca Uk Limited, this product is identified by NDC 60440-0960.

Identification & Billing

NDC Package Code
60440-0960-2
Package Description
457 IMPLANT in 1 BOX
Product Code
60440-0960
11-Digit Billing Format
60440096002

Clinical Specifications

Proprietary Name
Goserelin Acetate
Non-Proprietary Name
Goserelin Acetate
Substance Name
Goserelin Acetate
Dosage Form
Implant - A material containing drug intended to be inserted securely of deeply in a living site for growth, slow release, or formation of an organic union.
Active Ingredient(s)
GOSERELIN ACETATE 3.6 mg/1
Usage Information
Goserelin is used in men to treat prostate cancer. It is used in women to treat certain breast cancers or a certain uterus disorder (endometriosis). It is also used in women to thin the lining of the uterus (endometrium) in preparation for a procedure to treat abnormal uterine bleeding. Talk to your doctor about the risks and benefits of treatment. Goserelin is similar to a natural hormone made by the body (luteinizing hormone releasing hormone-LHRH). It works by decreasing testosterone hormones in men and estrogen hormones in women. This effect helps to slow or stop the growth of certain cancer cells and uterine tissue that need these hormones to grow and spread.

Regulatory & Marketing

Labeler Name
Astrazeneca Uk Limited
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
08-24-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60440-0960-2 identifies a specific commercial package of 457 implant in 1 box of Goserelin Acetate (UNFINISHED drug), drug for further processing labeled by Astrazeneca Uk Limited. This implant is formulated for use and contains goserelin acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Astrazeneca Uk Limited on August 24, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Goserelin is used in men to treat prostate cancer. It is used in women to treat certain breast cancers or a certain uterus disorder (endometriosis). It is also used in women to thin the lining of the uterus (endometrium) in preparation for a procedure to treat abnormal uterine bleeding. Talk to your doctor about the risks and benefits of treatment. Goserelin is similar to a natural hormone made by the body (luteinizing hormone releasing hormone-LHRH). It works by decreasing testosterone hormones in men and estrogen hormones in women. This effect helps to slow or stop the growth of certain cancer cells and uterine tissue that need these hormones to grow and spread.

How is this Astrazeneca Uk Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60440096002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
60440-0960-2
11-Digit CMS (5-4-2)
60440-0960-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.